AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMUGENE LTD

0.040

+0.00514.29%

Volume:65.79M

Turnover:2.49M

Market Cap:298.30M

PE:-2.27

High:0.040

Open:0.037

Low:0.036

Close:0.035

Loading ...

Overview Company News Filings

Imugene Receives Patent for Oncolytic Virus in China

MT Newswires Live

BRIEF-Imugene Says Oncarlytics Patent Allowance In China

Imugene Ltd - Oncarlytics Patent Allowance in China

THOMSON REUTERS

Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher

Imugene Therapy Achieves Two Complete Responses in Patients with Blood Cancer, Shares Rise Past 8%

MT Newswires Live

BRIEF-Imugene Receives A$20 Mln For Convertible Notes Issue

Imugene Receives AU$20 Million From First Tranche of AU$46 Million Capital Raise; Shares Down 3%

MT Newswires Live

Imugene Ltd - Imugene Receives a$20 Mln for Convertible Notes Issue

THOMSON REUTERS

Imugene Receives Nearly AU$12 Million R&D Tax Refund

MT Newswires Live

3 ASX All Ords shares leading the charge in 2025

Australian Shares End Week Higher; ASX Looks to Crack Down on Companies' Allegedly Misleading Disclosures

MT Newswires Live

Why Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higher

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

The Market Herald

Guess which ASX small cap stock is jumping on 'significant milestone'

Imugene Says First Australian Patient Dosed in Lymphoma Trial

MT Newswires Live

ASX Preview: Australian Shares to Open Lower Amid Wall Street Losses

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/IMU.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.04,"timestamp":1742361120000,"preClose":0.035,"halted":0,"volume":65794805,"delay":0,"changeRate":0.142857,"change":0.005,"floatShares":6260580705,"shares":7457433979,"eps":-0.017588,"lyrEps":-0.021115,"pbRate":4.71,"amount":2490965,"amplitude":0.114286,"volumeRatio":2.5504411855664166,"dividePrice":0,"prevYearClose":0.037,"fiveDayClose":0.031,"twentyDayClose":0.039},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":6260580705,"roa":"-42.92%","roe":"-100.19%","lyrEps":-0.021115,"volumeRatio":2.5504411855664166,"shares":7457433979,"dividePrice":0,"high":0.04,"amplitude":0.114286,"preClose":0.035,"low":0.036,"week52Low":0.031,"pbRate":"4.71","psRate":"-162.15","week52High":0.112,"institutionHeld":0,"latestPrice":0.04,"committee":-0.86663,"eps":-0.017588,"divideRate":0,"volume":65794805,"delay":0,"ttmEps":-0.017588,"open":0.037,"prevYearClose":0.037,"prevWeekClose":0.036,"prevMonthClose":0.037,"prevQuarterClose":0.037,"fiveDayClose":0.031,"twentyDayClose":0.039,"sixtyDayClose":0.036},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514807835","title":"Imugene Receives Patent for Oncolytic Virus in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514807835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514807835?lang=en_us&edition=fundamental","pubTime":"2025-02-26 10:15","pubTimestamp":1740536115,"startTime":"0","endTime":"0","summary":"Imugene  received a notice of allowance from the Chinese patent office for City of Hope's patent application for the CD19-expressing oncolytic virus, onCARlytics, according to a Wednesday Australian bourse filing.The patent protects the method of composition and method of use of onCARlytics through to 2038.OnCARlytics is exclusively licensed to Imugene and is a CD19-expressing oncolytic virus that enters solid tumor cells, forcing them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies.Its OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites in the US, with up to around 40 patients proposed to take part.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2514027090","title":"BRIEF-Imugene Says Oncarlytics Patent Allowance In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514027090","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514027090?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:58","pubTimestamp":1740535109,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Says Oncarlytics Patent Allowance In ChinaFeb 26 (Reuters) - Imugene Ltd IMU.AX:ONCARLYTICS PATENT ALLOWANCE IN CHINASource text: ID:nASX4H7R2BFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PG10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2514042775","title":"Imugene Ltd - Oncarlytics Patent Allowance in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514042775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514042775?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:59","pubTimestamp":1740520782,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2511687824","title":"Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2511687824","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511687824?lang=en_us&edition=fundamental","pubTime":"2025-02-14 10:02","pubTimestamp":1739498540,"startTime":"0","endTime":"0","summary":"In afternoon trade on Friday, theS&P/ASX 200 Index is on course to record a decent gain. At the time of writing, the benchmark index is up 0.4% to 8,574.7 points.Four ASX shares that are rising more than most today are listed below. Here's why they are charging higher:. The Temple & Webster share price is up a further 8% to $17.45. Investors have been bidding the furniture and homeware retailer's shares higher this week following the release of its half year results. Temple & Webster reported a 23.6% increase in revenue to $313.7 million and a 118% jump in net profit after tax to $9 million. The company's CEO, Mark Coulter, said: \"Temple & Webster has again delivered a record half, with strong performance against all key metrics, against a challenging macro and consumer backdrop.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/14/why-gqg-imugene-mirvac-and-temple-webster-shares-are-pushing-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7510","BK4211","BK7049","XJO.AU","TPW.AU","GQG.AU","MGR.AU","IMU.AU","BK7067","BK7087","BK7062","BK7107","WBS","BK7508"],"gpt_icon":0},{"id":"2511981683","title":"Imugene Therapy Achieves Two Complete Responses in Patients with Blood Cancer, Shares Rise Past 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511981683","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511981683?lang=en_us&edition=fundamental","pubTime":"2025-02-14 09:41","pubTimestamp":1739497315,"startTime":"0","endTime":"0","summary":"Imugene (ASX:IMU) reported two more complete responses in its phase 1b trial of azer-cel cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma, according to a Friday Australi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":1},{"id":"2507764495","title":"BRIEF-Imugene Receives A$20 Mln For Convertible Notes Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2507764495","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507764495?lang=en_us&edition=fundamental","pubTime":"2025-01-29 09:23","pubTimestamp":1738113794,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Receives A$20 Mln For Convertible Notes IssueJan 29 (Reuters) - Imugene Ltd IMU.AX:IMUGENE RECEIVES A$20 MILLION FOR CONVERTIBLE NOTES ISSUEFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OO1S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2507573925","title":"Imugene Receives AU$20 Million From First Tranche of AU$46 Million Capital Raise; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507573925","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507573925?lang=en_us&edition=fundamental","pubTime":"2025-01-29 08:26","pubTimestamp":1738110396,"startTime":"0","endTime":"0","summary":"Imugene  received AU$20 million from the issuance of senior, unsecured, zero-coupon convertible notes to CVI Investments, representing the first tranche of a AU$46 million capital raise, according to a Wednesday filing with the Australian bourse.The convertible notes have a five-year maturity, the filing said.Proceeds will be used to advance the company's immuno-oncology clinical trial pipeline, according to the filing.Imugene's shares fell nearly 3% in morning trade Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2507526285","title":"Imugene Ltd - Imugene Receives a$20 Mln for Convertible Notes Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2507526285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507526285?lang=en_us&edition=fundamental","pubTime":"2025-01-29 05:21","pubTimestamp":1738099272,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO1S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2502000806","title":"Imugene Receives Nearly AU$12 Million R&D Tax Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2502000806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502000806?lang=en_us&edition=fundamental","pubTime":"2025-01-10 12:19","pubTimestamp":1736482763,"startTime":"0","endTime":"0","summary":"Imugene  received a tax refund of AU$11.7 million for the fiscal year ended June 30, 2023, from the Australian federal government's research and development tax incentive scheme, according to a Friday filing with the Australian bourse.The scheme encourages Australian firms to conduct research and development activities by providing a refund for eligible expenditures.Funds from the rebate will be used by the immunotherapy firm to advance the development of products in the pipeline, the filing said.The company's shares fell past 2% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7508","XKO.AU","XAO.AU","XJO.AU","BK7067"],"gpt_icon":0},{"id":"2502009293","title":"3 ASX All Ords shares leading the charge in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502009293","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502009293?lang=en_us&edition=fundamental","pubTime":"2025-01-10 10:55","pubTimestamp":1736477701,"startTime":"0","endTime":"0","summary":"Although under pressure today, the All Ordinaries Index is up 1.3% so far in 2025, with three ASX All Ords shares racing ahead of those gains. At market close yesterday, these three companies were leading the charge higher in the nascent new year. You'll also notice a decided trend in the sector they operate in. Which soaring ASX All Ords shares are we talking about?) The EBR Systems share price closed out 2024 at $1.025. In Friday afternoon trade, shares are changing hands for $1.40 apiece. That sees this ASX All Ords stock up 36.6% already in the new year. On Monday, the company, which is developing the world's only wireless cardiac pacing device for heart failure , reported that the US Food and Drug Administration  had scheduled the manufacturing Pre-Approval Inspection  to commence on 14 January. \"This significant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/3-asx-all-ords-shares-leading-the-charge-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","PAI.AU","EBR.AU","XJO.AU","IMU.AU","BK7508","XKO.AU","BK7007","CYC.AU","BK7067","PAI"],"gpt_icon":0},{"id":"2500159085","title":"Australian Shares End Week Higher; ASX Looks to Crack Down on Companies' Allegedly Misleading Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2500159085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500159085?lang=en_us&edition=fundamental","pubTime":"2025-01-03 14:06","pubTimestamp":1735884405,"startTime":"0","endTime":"0","summary":"Australian shares closed the week higher, tracking Asian markets, despite Wall Street's concerns about high interest rates.The S&P/ASX 200 Index rose 0.6% or 49.3 points to close at 8,250.5.Anticipated fewer rate cuts from the US Federal Reserves, coupled with potential inflationary policies from President-elect Trump hit shares while sending bond yields higher and making the dollar stronger, Reuters reported.In company news, the Australian Securities Exchange  is looking to clamp down on listed companies allegedly providing misleading or evasive information in their market disclosures, according to a report by The Australian.Imugene  dosed the first Australian patient for its phase 1b clinical trial of its CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital in Sydney.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7039","ASX.AU","XJO.AU","IMU.AU","BK7067","XAO.AU","XKO.AU","BK7508"],"gpt_icon":0},{"id":"2500135962","title":"Why Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2500135962","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500135962?lang=en_us&edition=fundamental","pubTime":"2025-01-03 09:31","pubTimestamp":1735867866,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is fighting hard to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 8,232.7 points. Four ASX shares that are rising more than mos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/why-cettire-gold-road-imugene-and-paladin-energy-shares-are-racing-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7049","BK7021","BK1229","CTT.AU","IMU.AU","PDN.AU","BK7506","BK7509","BK7083","XAO.AU","XJO.AU","GOR.AU","XKO.AU","BK7104","BK7067","00495","BK7508","BK1258"],"gpt_icon":0},{"id":"2500115816","title":"First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care","url":"https://stock-news.laohu8.com/highlight/detail?id=2500115816","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500115816?lang=en_us&edition=fundamental","pubTime":"2025-01-03 08:56","pubTimestamp":1735865760,"startTime":"0","endTime":"0","summary":"Imugene Limited  has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic CAR T-cell therapy Azer-cel treatment at the Royal Prince Alfred Hospital in Sydney earlier this week.This dosage marks the start of Imugene’s Phase 1b trials, which are now mainly focusing on one of the most challenging and aggressive forms of non-Hodgkin’s lymphoma.The idea, the biotechnology company has suggested several times through early testing, is that Azer-cel would offer an off-the-shelf alternative to traditional CAR T-cell therapies – most of which still need lengthy manufacturing that needs patients to share cells and can carry long treatment timelines and costs.This spearhead into Aussie testing comes after Imugene collected “promising data” through its U.S.-based trials; three patients in State-side testing had zero signs of the cancer despite relapsing after other, similar treatments.The material provided in this article is for information only and shou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/first-aussie-doses-bring-imugene-major-step-closer-to-quicker-cheaper-non-hodgkins-lymphoma-care-2025-01-03/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","XAO.AU","IMU.AU","BK7508","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2500180952","title":"Guess which ASX small cap stock is jumping on 'significant milestone'","url":"https://stock-news.laohu8.com/highlight/detail?id=2500180952","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500180952?lang=en_us&edition=fundamental","pubTime":"2025-01-03 08:28","pubTimestamp":1735864080,"startTime":"0","endTime":"0","summary":"Imugene Ltd  shares are ending the week on a positive note. In late morning, trade, the ASX small cap stock is up 5% to 4.1 cents. Why is this ASX small cap stock roaring higher?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/guess-which-asx-small-cap-stock-is-jumping-on-significant-milestone/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4161","BK7508","BK7067","CR","IMU.AU","XAO.AU","XJO.AU","XKO.AU"],"gpt_icon":0},{"id":"2500573186","title":"Imugene Says First Australian Patient Dosed in Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2500573186","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500573186?lang=en_us&edition=fundamental","pubTime":"2025-01-03 07:19","pubTimestamp":1735859972,"startTime":"0","endTime":"0","summary":"Imugene  the first Australian patient has been dosed in the phase 1b clinical trial of its CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital in Sydney, according to a Friday filing with the Australian bourse.The trial assesses the safety, tolerability, and clinical activity of azer-cel in patients with relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin's lymphoma, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7067","XAO.AU","XKO.AU","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2500918311","title":"ASX Preview: Australian Shares to Open Lower Amid Wall Street Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2500918311","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500918311?lang=en_us&edition=fundamental","pubTime":"2025-01-03 06:40","pubTimestamp":1735857627,"startTime":"0","endTime":"0","summary":"Australian shares are expected to slip into the red at market open Friday as investors follow losses from Wall Street overnight.The Nasdaq and the S&P 500 shed 0.2% each on Thursday, with Tesla driving the losses following a drop in vehicle deliveries for 2024. The Dow Jones Industrial Average was down 0.4%.In macroeconomic news, the commodity price index rose 0.6% month over month in December 2024 in special drawing rights  terms, following a revised 1.3% increase in the prior month, preliminary data from the Reserve Bank of Australia showed Thursday.In corporate news, Imugene  dosed the first Australian patient in the Phase 1b clinical trial of its azer-cel therapy, which is being assessed as a potential treatment for non-Hodgkin's lymphoma.Arcadium Lithium  and Livent entered into a second supplemental indenture on Jan. 1.UBS Securities Australia ceased to be a substantial holder in SG Fleet Group .Australia's benchmark index rose 0.5%, or 42.10 points, Thursday to close at 8,201.20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7064","BK7016","BK7067","BK7508","XJO.AU","XKO.AU","SDR.AU","XAO.AU","LTM.AU","BK7036","SGF.AU","SDR"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":50}]}}